江苏康缘药业股份有限公司 | 姓名 | 职务 | 获授的限制性股 | 占限制性股票 | 占本计划公告日 | | --- | --- | --- | --- | --- | | | | 票数量（万股） | 总数的比例 | 总股本的比例 | | 鲜飞鹏 | 副总经理 | 8.00 | 0.91% | 0.01% | | 江锁成 | 财务总监 | 5.00 | 0.57% | 0.01% | | 中层管理人员及核心骨干（12 | 人） | 50.10 | 5.69% | 0.09% | | 小计（14 | 人） | 63.10 | 7.17% | 0.11% | 注：1、上述任何一名激励对象通过全部有效的股权激励计划获授的本公司股票均未超 过公司总股本的 1%。公司全部有效的激励计划所涉及的标的股票总数累计不超过公司股本 总额的 10%。 2、本激励计划激励对象不包括独立董事、监事及单独或合计持有公司 5%以上股份的 股东或实际控制人及其配偶、父母、子女。 3、上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致。 二、中层管理人员及核心骨干人员名单（排名无先后） | 序号 | 姓名 | 职务 | | ...

证券简称：康缘药业 证券代码：600557 公告编号：2023-036 江苏康缘药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可以在 2023 年 9 月 13 日(星期三)至 9 月 15 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目进行提问，公司将在说明会上 就投资者普遍关注的问题进行解答。 一、说明会类型 江苏康缘药业股份有限公司（以下简称"公司"）于 2023 年 7 月 13 日在 上海证券交易所网站www.sse.com.cn披露了《江苏康缘药业股份有限公司 2023 年半年度报告》。为使广大投资者更全面深入地了解公司情况，公司将通过网 络方式举行"康缘药业 2023 年半年度业绩说明会"，对公司 2023 年上半年的 经营情况、财务状况等事项与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行解答。 二、说明会召开的时间和地点 财务总监：江锁成先生 董事兼董事会秘书 ...

证券简称：康缘药业 证券代码：600557 公告编号：2023-034 临床前主要药效学研究显示，乌鳖还闺颗粒对卵巢早衰模型具有明显的治疗 作用，能够延长卵巢早衰模型动物的动情期，缩短动情间期及动情周期，具有促 江苏康缘药业股份有限公司 关于收到乌鳖还闺颗粒临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江苏康缘药业股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局签发的乌鳖还闺颗粒《药物临床试验批准通知书》。按照上海证券交易所《上 海证券交易所上市公司自律监管指引第 3 号—行业信息披露》的相关要求，现将 相关情况公告如下： 二、药品研发及相关情况 乌鳖还闺颗粒处方源于国医大师夏桂成教授临床经验方，功能主治为补肾健 脾、调理冲任，主要用于治疗早发性卵巢功能不全，症见月经稀发量少、甚则闭 经，胸闷心慌、腰膝酸软、失眠多梦、健忘、烘热出汗等。 药品名称 乌鳖还闺颗粒 适应症 早发性卵巢功能不全中医辨证属肾阴虚证 注册分类 中药创新药 1.1 类 剂型 颗粒剂 申请人 江苏康缘药业股份有限 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江苏康缘药业股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局核准签发的关于 KYS202002A 注射液成人系统性红斑狼疮适应症的《药物 临床试验批准通知书》。KYS202002A 是由公司开发的一种全人源抗 CD38 单克 隆抗体，该新药前期已在中国、美国获得复发和难治性多发性骨髓瘤适应症临床 研究许可，相关情况详见公司分别于 2023 年 1 月 11 日、2023 年 6 月 27 日在上 海证券交易所网站 www.sse.com.cn 披露的公司《关于收到 KYS202002A 注射液 临床试验批准通知书的公告》（公告编号：2023-003）、《关于 KYS202002A 注 射液获得美国 FDA 临床试验批准的公告》（公告编号：2023-025），目前已启动 中国复发和难治性多发性骨髓瘤适应症 I 期临床研究。本次获批成人系统性红斑 狼疮适应症《药物临床试验批准通知书》相关情况如下： 证券简称：康缘药业 证券代码：600557 公告编号：2023-03 ...

证券代码：600557 证券简称：康缘药业 公告编号：2023-032 江苏康缘药业股份有限公司 2022 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.22 元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2023/8/22 | － | 2023/8/23 | 2023/8/23 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2023 年 6 月 26 日的 2022 年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2022 年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本 584, ...

Financial Performance - Total operating revenue for the first half of 2023 reached ¥2,553,167,904.18, an increase of 21.7% compared to ¥2,097,177,339.38 in the same period of 2022[11]. - Net profit for the first half of 2023 was ¥334,746,398.79, compared to ¥251,195,552.65 in the first half of 2022, representing a growth of 33.2%[11]. - The company's operating revenue for the first half of 2023 reached CNY 2,410,524,559.94, representing a 23.2% increase from CNY 1,954,559,561.41 in the same period of 2022[15]. - Net profit attributable to shareholders of the parent company was CNY 275,720,868.32, up 30.6% from CNY 211,120,583.32 year-on-year[12]. - Total comprehensive income for the period was CNY 282,889,034.97, compared to CNY 211,364,180.66 in the first half of 2022, marking a 33.8% increase[12]. Assets and Liabilities - As of June 30, 2023, the total current assets amounted to CNY 3,771,501,855.17, a slight increase from CNY 3,729,859,645.62 as of December 31, 2022, representing a growth of approximately 1.1%[2]. - The total non-current assets decreased to CNY 3,032,851,520.74 from CNY 3,065,944,555.74, indicating a decline of about 1.1%[3]. - The total assets of the company reached CNY 6,804,353,375.91, up from CNY 6,795,804,201.36, reflecting a marginal increase of approximately 0.1%[4]. - Total liabilities decreased to CNY 1,694,500,889.52 from CNY 1,861,811,589.74, showing a reduction of about 9%[4]. - The total equity attributable to shareholders increased to CNY 4,925,246,004.02 from CNY 4,754,194,495.90, marking an increase of approximately 3.6%[4]. Cash Flow - The company's operating cash inflow for the first half of 2023 was CNY 2,979,346,456.08, an increase of 25.7% compared to CNY 2,370,291,696.69 in the same period of 2022[22]. - The net cash flow from operating activities was CNY 456,366,532.43, up from CNY 374,551,870.05 in the first half of 2022, representing a growth of 21.9%[22]. - The total cash and cash equivalents at the end of the period reached CNY 1,977,320,416.17, up from CNY 957,364,934.32 at the end of the first half of 2022[24]. Research and Development - Research and development expenses increased to ¥363,451,324.29 in the first half of 2023, compared to ¥277,402,732.74 in the same period of 2022, marking a rise of 31%[11]. - Research and development expenses amounted to CNY 350,669,094.98, which is a 33.0% increase from CNY 263,637,771.87 in the first half of 2022[15]. - The company has established an advanced innovative drug research and development system, focusing on developing innovative drugs with clinical advantages and characteristics[68]. Market and Product Development - The company plans to continue expanding its market presence and investing in new product development to sustain growth[20]. - The company is focused on innovation in traditional Chinese medicine and actively expanding into chemical and biological pharmaceuticals[52]. - The company has a diverse product line targeting respiratory, gynecological, cardiovascular, and orthopedic diseases, with several new drugs under development[52]. - The company plans to launch three new products in the next quarter, focusing on innovative drug formulations[161]. Corporate Governance - The board of directors was expanded from 7 to 9 members, and the supervisory board from 3 to 5 members, to enhance corporate governance[198]. - The company has completed the election of the board of directors and supervisory board, as well as the appointment of senior management[200]. - The company is focusing on improving its internal governance structure to align with its growth objectives[198]. Strategic Initiatives - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[105]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of CNY 500 million allocated for this purpose[108]. - Future guidance indicates a revenue target of CNY 2.5 billion for the full year 2023, representing a growth rate of 12%[104]. Quality Control and Compliance - The company has established a strict quality control mechanism for its products, ensuring that raw materials meet higher internal standards than legal requirements[138]. - The company emphasizes the importance of accurate measurement and reporting of financial assets and liabilities to mitigate accounting mismatches[63]. - The company has implemented a systematic approach to amortize contract costs, ensuring that costs related to contract performance are recognized as assets when they meet specific criteria[148].

证券简称：康缘药业 证券代码：600557 公告编号：2023-013 江苏康缘药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可以在 2023 年 5 月 10 日(星期三)至 5 月 12 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 （fzb@kanion.com）进行提问，公司将在说明会上就投资者普遍关注的问题进行 解答。 一、说明会类型 江苏康缘药业股份有限公司（以下简称"公司"）于 2023 年 2 月 21 日在 《上海证券报》《中国证券报》《证券日报》《证券时报》及上海证券交易所 网站www.sse.com.cn披露了《江苏康缘药业股份有限公司 2022 年年度报告》， 于 2023 年 4 月 8 日在《上海证券报》《中国证券报》《证券日报》《证券时 报》及上海证券交易所网站www.sse.com.cn披露了《江苏康缘药业股份有限公 司 2023 年第 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,352,493,841.95, representing a 25.39% increase year-over-year[19]. - The net profit attributable to shareholders for Q1 2023 was CNY 141,438,358.86, reflecting a 28.60% increase compared to the same period last year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 139,362,939.64, up 30.70% year-over-year[19]. - The basic earnings per share for Q1 2023 was CNY 0.25, an increase of 31.58% compared to the previous year[19]. - The diluted earnings per share for Q1 2023 was CNY 0.24, reflecting a 26.32% increase year-over-year[19]. - Net profit for Q1 2023 was ¥145,272,114.36, compared to ¥110,378,236.08 in Q1 2022, representing a 31.6% growth[45]. - Total comprehensive income amounts to 145,272,114.36, an increase from 110,378,236.08[49]. - Total comprehensive income attributable to the parent company is 141,438,358.86, up from 109,985,159.38[49]. Cash Flow and Assets - The net cash flow from operating activities was CNY -60,672,699.77, a decrease of 176.67% compared to the same period last year[19]. - Cash flow from operating activities in Q1 2023 showed a net outflow of ¥60,672,699.77, compared to a net inflow of ¥79,139,904.88 in Q1 2022[46]. - The total assets at the end of Q1 2023 were CNY 6,718,199,483.33, a decrease of 1.14% from the end of the previous year[19]. - The total assets as of Q1 2023 were ¥6,718,199,483.33, down from ¥6,795,804,201.36 in the previous year[43]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,177, with Jiangsu Kangyuan Group Co., Ltd. holding 30.14% of shares[25]. - The equity attributable to shareholders at the end of Q1 2023 was CNY 4,895,632,854.76, representing a 2.98% increase from the end of the previous year[19]. - The total equity attributable to shareholders of the parent company is 4,895,632,854.76 RMB, an increase from 4,754,194,495.90 RMB[29]. Liabilities - The total liabilities amount to 1,641,294,557.35 RMB, down from 1,861,811,589.74 RMB in the previous period[29]. - The company’s total liabilities decreased from ¥1,781,105,699.00 in the previous year to ¥1,561,334,431.09 in Q1 2023, a decline of approximately 12.3%[43]. - The total non-current liabilities amount to 79,960,126.26 RMB, slightly down from 80,705,890.74 RMB[29]. Research and Development - Research and development expenses in Q1 2023 amounted to ¥188,577,937.82, an increase from ¥144,196,379.61 in Q1 2022, indicating a 30.8% rise[44]. Other Financial Information - The company recorded a government subsidy of 4,035,535.94 RMB, which is closely related to its normal business operations[21]. - The company experienced a loss of 253,015.40 RMB from the disposal of non-current assets[21]. - The company’s investment income for Q1 2023 was ¥447,980.55, down from ¥1,127,010.39 in Q1 2022, reflecting a decrease of 60.3%[44]. - The net profit attributable to the parent company's shareholders is 141,438,358.86, up from 109,985,159.38[49]. - The net profit attributable to minority shareholders is 3,833,755.50, compared to 393,076.70 previously[49]. - The company did not apply new accounting standards or interpretations starting in 2023[51].

Share Capital and Financial Performance - The company issued a total of 584,597,952 shares by the end of 2022, a decrease of 8,283,086 shares compared to the beginning of the year[2]. - As of December 31, 2022, the company's distributable profit amounted to ¥3,843,349,759.05[198]. - The total share capital as of December 31, 2022, was 584,597,952 shares[198]. - The board proposed a cash dividend of ¥2.20 per 10 shares (tax included), totaling approximately ¥128,611,549.44 to be distributed to shareholders[198]. - The company achieved a consolidated revenue of CNY 4,350.87 million, representing a year-on-year increase of 19.25%[60]. - The net profit attributable to shareholders increased by 35.54% to CNY 434.47 million[60]. - The company reported a weighted average return on equity of 9.61%, an increase of 2.04 percentage points year-on-year[60]. - Total operating cash flow for the period was approximately ¥995.94 million, an increase of 9.65% compared to the previous year[47]. - The company’s cash and cash equivalents at the end of the period amounted to ¥1,601.30 million, representing 23.56% of total assets, a 70.82% increase from the previous year[48]. - The company achieved a net profit of CNY 300 million, which is a 20% increase compared to the previous year[179]. Research and Development - The company invested significantly in R&D, with a notable increase in prepayments for R&D expenses, contributing to an 86.49% rise in prepayments compared to the previous year[49]. - Research and development expenses totaled CNY 621.17 million, accounting for 14.28% of total revenue[69]. - The company has a strong R&D team, consisting of 203 master's degree holders and 18 doctoral researchers[46]. - The company is committed to strengthening its research and development capabilities by building specialized research teams and enhancing quality control processes[117]. - The company has established a technical committee composed of industry experts to enhance the R&D team and improve the drug development process[120]. - The company is actively pursuing major scientific research projects and enhancing intellectual property protection to build innovation barriers[91]. - The company aims to achieve breakthroughs in innovative drug development in major diseases and other areas aligned with its sales model[26]. - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for the development of new traditional Chinese medicine products[135]. Market and Sales Performance - The company achieved strong growth in core products, focusing on Ginkgo Biloba Terpene Lactone Injection and Jin Zhen Oral Liquid, breaking the previous dominance of Heat Toxicity Ning Injection[9]. - The company's revenue from domestic sales in the industrial sector reached CNY 4,323,415,556.38, representing a year-on-year increase of 19.64%[37]. - The revenue from injectable and oral liquid products was CNY 1,451,284,288.00 and CNY 1,122,387,070.56, with respective gross profit margins of 73.61% and 80.07%[37]. - The sales revenue of gel products increased by 417.69% year-on-year, primarily due to the growth in sales of muscle and joint pain relief gel[38]. - The revenue from oral liquid products surged by 68.45%, driven by increased sales of Jinzhen oral liquid[63]. - The company is focused on maintaining steady revenue and profit growth by leveraging its diverse product portfolio and improving management practices[93]. - The company aims to enhance sales growth by focusing on core products and expanding its OTC business, targeting major retail chains[90]. - Future outlook indicates a projected revenue growth of 10% for 2023, driven by new product launches and market expansion strategies[135]. Operational Efficiency and Management - The company has established a comprehensive production plan based on sales forecasts and real-time inventory, ensuring optimized resource allocation[27]. - The company has implemented a digital extraction and refining factory, recognized as a pilot demonstration project by the Ministry of Industry and Information Technology[34]. - The company’s intelligent manufacturing project has set a benchmark for the transformation of traditional Chinese medicine manufacturing to intelligent production[33]. - The company has implemented advanced quality control technologies throughout the production process to ensure the stability and safety of its products[147]. - The company is focused on mitigating drug quality risks through improved management practices across the supply chain[119]. - The company has implemented a comprehensive upgrade of its ERP system to improve operational management and supply chain efficiency[92]. - The company aims to improve operational efficiency, targeting a 10% reduction in production costs through process optimization[135]. Corporate Governance and Compliance - The company has implemented strict insider information management protocols to ensure compliance during the reporting period[127]. - The company has established a comprehensive information disclosure system to prevent selective disclosure and insider trading, ensuring all shareholders have equal access to information[151]. - The company has adhered to legal requirements in convening shareholder meetings, ensuring equal rights for all shareholders, especially minority shareholders[122]. - The company has not reported any measures affecting its independence from controlling shareholders[128]. - The company maintains independence from its controlling shareholder in operations, finance, and business, ensuring fair and reasonable related party transactions[150]. - The company assures that the annual report's financial statements are true, accurate, and complete[197]. Strategic Initiatives and Future Plans - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[135]. - The company is advancing research on already listed products to build a robust evidence chain for clinical and foundational studies, while also pursuing international drug registration for traditional Chinese medicine[144]. - The company aims to align its social responsibility with competitive advantages to achieve coordinated development in economic, social, and environmental benefits[115]. - The company plans to launch three new products in the upcoming quarter, targeting unmet medical needs[179]. - The company has set a target to launch at least five new products in the next fiscal year, focusing on innovative herbal formulations[135]. - A strategic partnership with a leading research institution has been established to enhance product efficacy and safety[135]. - The company is committed to sustainability initiatives, allocating CNY 50 million for environmental projects[179]. Industry Trends and Market Conditions - The total healthcare expenditure in China reached RMB 7.6845 trillion in 2021, growing approximately fourfold over the past decade, indicating a robust market for the pharmaceutical industry[18]. - The pharmaceutical industry in China has seen a nearly sixfold increase in asset scale over the past ten years, with a compound annual growth rate of 20.4%[18]. - The pharmaceutical industry is significantly influenced by government policies, with ongoing centralized procurement measures expected to impact the market[146].

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,028,314,291.81, representing a 26.25% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was ¥70,217,175.01, an increase of 47.48% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥61,245,927.71, reflecting a 38.70% increase compared to the previous year[5]. - Total operating revenue for the first three quarters of 2022 reached CNY 3,125,491,631.19, an increase of 21% compared to CNY 2,583,608,207.75 in the same period of 2021[22]. - Net profit for the third quarter of 2022 was CNY 283,974,013.13, up 35% from CNY 210,413,540.55 in the third quarter of 2021[24]. - Basic earnings per share for Q3 2022 were CNY 0.49, up from CNY 0.36 in Q3 2021, indicating a 36% increase[26]. Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥6,153,703,406.73, a 2.25% increase from the end of the previous year[6]. - The total assets of the company as of September 30, 2022, were RMB 6,153,703,406.73, compared to RMB 6,018,019,235.83 at the end of 2021, marking a growth of about 2.2%[18]. - The total liabilities decreased to CNY 1,393,009,092.14 in Q3 2022 from CNY 1,545,298,934.37 in Q3 2021, a reduction of approximately 10%[21]. - The company's total equity increased to CNY 4,760,694,314.59 in Q3 2022, compared to CNY 4,472,720,301.46 in Q3 2021, reflecting a growth of about 6%[21]. Cash Flow - The company reported a cash flow from operating activities of ¥612,508,012.74 for the year-to-date, a decrease of 10.37% compared to the previous year[5]. - Cash flow from operating activities for the first three quarters of 2022 was CNY 3,506,264,851.49, compared to CNY 3,223,675,434.45 in the same period of 2021, marking an increase of 9%[26]. - The net cash flow from operating activities for Q3 2022 was CNY 612,508,012.74, a decrease of 10.4% compared to CNY 683,361,113.13 in Q3 2021[27]. - Total cash inflow from operating activities reached CNY 3,662,711,565.24, up 8.7% from CNY 3,367,959,216.39 in the same period last year[27]. - Cash outflow from operating activities was CNY 3,050,203,552.50, an increase of 13.6% compared to CNY 2,684,598,103.26 in Q3 2021[27]. Shareholder Information - The company has a total of 30,074 common shareholders at the end of the reporting period[9]. - The largest shareholder, Jiangsu Kangyuan Group Co., Ltd., holds 30.14% of the shares[9]. Research and Development - Research and development expenses for the first three quarters of 2022 amounted to CNY 437,120,488.39, representing a 30% increase from CNY 336,806,040.18 in the same period of 2021[22]. Inventory and Receivables - The company's inventory decreased to RMB 236,822,438.27 from RMB 338,077,195.06, reflecting a decline of approximately 30%[16]. - Accounts receivable rose to RMB 768,709,052.89, up from RMB 732,061,053.66, indicating an increase of approximately 5%[16]. Financial Management - The company reported a financial expense of CNY -5,239,101.37 in the first three quarters of 2022, a significant improvement compared to CNY 7,282,044.93 in the same period of 2021[22]. - The net cash flow from investing activities was -CNY 195,128,177.52, an improvement from -CNY 233,639,277.64 in Q3 2021[27]. - The net cash flow from financing activities was -CNY 168,289,256.11, an improvement from -CNY 438,458,725.39 in the same quarter last year[29].